Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organovo

3.14
-0.5344-14.54%
Post-market: 3.12-0.0200-0.64%19:50 EDT
Volume:505.38K
Turnover:1.77M
Market Cap:5.34M
PE:-0.32
High:4.15
Open:3.70
Low:3.06
Close:3.67
Loading ...

Company Profile

Company Name:
Organovo
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
14
Office Location:
11555 Sorrento Valley Road,Suite 100,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Directors

Name
Position
Keith Murphy
Director and Executive Chairman
Douglas Jay Cohen
Lead Independent Director
Adam Stern
Director
Alison Tjosvold Milhous
Director
David Gobel
Director
Vaidehi Joshi
Director

Shareholders

Name
Position
Thomas Hess
President and Chief Financial Officer
Keith Murphy
Director and Executive Chairman